Cidara Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Cidara Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Cidara Therapeutics Q1 2025 10-Q filed. Financials updated.
AI Summary
Cidara Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as K2 Therapeutics, Inc., is focused on biological products. Key financial data and stock information are detailed within the filing.
Why It Matters
This filing provides investors with an update on Cidara Therapeutics' financial health and operational status for the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a biotechnology company, Cidara Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is provided.)
- 2025-05-08 — Filing Date (The date the 10-Q report was officially submitted to the SEC.)
Key Players & Entities
- Cidara Therapeutics, Inc. (company) — Filer of the 10-Q report.
- K2 Therapeutics, Inc. (company) — Former name of Cidara Therapeutics, Inc.
- 20250331 (date) — End of the reporting period for the 10-Q.
- 20250508 (date) — Date the 10-Q was filed.
- 6310 NANCY RIDGE DRIVE (location) — Business and mailing address of Cidara Therapeutics.
FAQ
What is the primary business of Cidara Therapeutics, Inc.?
Cidara Therapeutics, Inc. is primarily involved in the biological products sector, specifically classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
When did Cidara Therapeutics, Inc. change its name from K2 Therapeutics, Inc.?
The date of the name change from K2 Therapeutics, Inc. to Cidara Therapeutics, Inc. was June 11, 2014.
What is the fiscal year end for Cidara Therapeutics, Inc.?
The fiscal year end for Cidara Therapeutics, Inc. is December 31.
What is the SEC file number for Cidara Therapeutics, Inc.?
The SEC file number for Cidara Therapeutics, Inc. is 001-36912.
What is the business address of Cidara Therapeutics, Inc.?
The business address for Cidara Therapeutics, Inc. is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA 92121.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Cidara Therapeutics, Inc..